Clinical Trial: A Phase II exploratory study of Ipilimumab N01 in combination with Sintilimab and platinum-based chemotherapy as first-line treatment for locally advanced or metastatic NSCLC with SMARCA4 mutation or deficiency, or STK11/KEAP1 mutations (China)

China, Sept. 1 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Phase II exploratory study of Ipilimumab N01 in combination with Sintilimab and platinum-based chemotherapy as first-line treatment for locally advanced or metastatic NSCLC with SMARCA4 mutation or deficiency, or STK11/KEAP1 mutations'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131208

Registration Time: 2026/08/31

Type: Interventional study

Primary Sponsor: Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337482

Published by HT Digital Conten...